A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer is a phase 2/3, randomised interventional study registered as NCT07318883 by Shanghai Henlius Biotech, with a registry enrolment figure of 720 participants, started 2026-03 and due to reach its primary completion in 2031-01. Interventions recorded: HLX07; HLX07 placebo; Serplulimab; Pembrolizumab; Carboplatin; Paclitaxel or Nab-Paclitaxel. Conditions listed: Squamous NSCLC. Primary outcome: ORR assessed by BICR (part I); PFS assessed by BICR (part I); PFS assessed by BICR (part II). Lung eligibility wording from the registry: "Histologically confirmed with stage IIIB/IIIC or IV (AJCC 8th edition) squamous NSCLC ineligible for surgery or radical radiotherapy". Sites: China. No results are recorded here; the registry entry is the source.